ERBB2 and breast carcinoma: Our candidate selection of IgEs 20, 23 and 26 was based on biophysical attributes, recognition of human and rat homologues of HER2 (to allow for the development of suitable human and rat breast cancer surrogate models), epitope reactivity, and Fc-mediated effector potency.